News & Updates
Filter by Specialty:
Post-treatment HBsAg loss greater with TDF vs entecavir
In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.
Post-treatment HBsAg loss greater with TDF vs entecavir
12 Jun 2023Vaccination uptake among kids in SG: Flu shots lag behind pneumococcal vax
Not enough children in Singapore are getting vaccinated against influenza, whereas the number of those who are receiving pneumococcal shots has steadily increased over time.
Vaccination uptake among kids in SG: Flu shots lag behind pneumococcal vax
08 Jun 2023T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
07 Jun 2023Influenza linked to neurologic comorbidities in children
Influenza in a paediatric population can manifest as a neurologic disease, particularly as febrile seizures, according to a study. Hospitalized children with neurologic manifestation of influenza (neuro-flu) experience several neurologic comorbidities, which suggest that this condition is driven by host-factors rather than by pathogen-factors.
Influenza linked to neurologic comorbidities in children
01 Jun 2023First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
31 May 2023Vaccination protects the young against COVID-19
COVID-19 remains a global health concern, and children and adolescents are equally affected. In fact, COVID-19 hospitalization rates in children increased during the Omicron era. [MMWR 2022;71:271-278] In children aged 5–11 years who were hospitalized during the predominance of Omicron, nearly 90 percent were unvaccinated. [MMWR 2022;71:574-581]